Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 14/20 | 0.45 |
| ▸ | HTR1D | P28221 | 4/20 | 0.41 |
| ▸ | HTR1B | P28222 | 4/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100983 | 1.00 | GHSR (0.45) | GHSRHTR1DHTR1BHTR1ATSHR | |
| SCHEMBL6610281 | 0.92 | GHSR (0.44) | GHSRHTR1DHTR1BHTR1A | |
| SCHEMBL6610276 | 0.92 | GHSR (0.44) | GHSRHTR1DHTR1BHTR1A | |
| SCHEMBL6100745 | 0.85 | HTR1B (0.45) | GHSRHTR1DHTR1BHTR1ATSHR | |
| SCHEMBL6604341 | 0.85 | HTR1B (0.45) | GHSRHTR1DHTR1BHTR1ATSHR | |
| SCHEMBL6099305 | 0.82 | HTT (0.35) | GHSRHTR1DHTR1B | |
| SCHEMBL6099303 | 0.82 | HTT (0.35) | GHSRHTR1DHTR1B | |
| SCHEMBL6101343 | 0.81 | HTT (0.45) | GHSR | |
| SCHEMBL6959227 | 0.81 | HTT (0.37) | GHSR | |
| SCHEMBL6101478 | 0.81 | HTT (0.37) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-7109201-B2 | Piperazine derivatives, their preparation and uses in therapy | SMITHKLINE BEECHAM PLC (GB) | 2006-09-19 | — | — | US | disclosed |
| EP-1368337-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM P.I.C. | 2004-09-09 | — | — | US | disclosed |
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6747030-B1 | CIS-6-(3,5-DIMETHYLPIPERAZIN-1-YL)-5-METHOXY-1-(2'-METHYL-4'-( 5-METHYL-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-CARBONYL)INDOLINE, ITS HYDROCHLORIDE SALT, OR ANOTHER PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTIDEPRESSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-06-08 | — | — | US | disclosed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | disclosed |
| EP-1368337-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002074764-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | HTR1B, HTR2B, HTR2A | GHSR 245/4885HTR1D 8/4885HTR1B 1/4885 |
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | NR3C2, NR2C2, NR3C1 | GHSR 270/4885HTR1D 294/4885HTR1B 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.